Company Website:
http://www.rosenlegal.com/cases-1100.html
NEW YORK -- (Business Wire)
Rosen Law Firm, a global investor rights law firm, reminds purchasers of
Lion Biotechnologies, Inc. securities (NASDAQ: LBIO) from November 14,
2013 through April 10, 2017, inclusive (the “Class Period”) of the
important June 13, 2017 lead plaintiff deadline in the first filed
lawsuit commenced by Rosen Law Firm. The lawsuit seeks to recover
damages for Lion Biotechnologies investors under the federal securities
laws.
To join the Lion Biotechnologies class action, go to http://www.rosenlegal.com/cases-1100.html
or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653
or email pkim@rosenlegal.com or kchan@rosenlegal.com
for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS
CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU
MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU
MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made
false and/or misleading statements and/or failed to disclose that (1)
Lion Biotechnologies, through its former CEO Manish Singh, engaged in a
scheme to mislead investors by commissioning over 10 internet
publications and 20 widely distributed emails promoting Lion
Biotechnologies to potential investors that purported to be independent
from the company when, in fact, they were paid promotions; (2) former
CEO Singh engaged a notorious stock promotion firm to pay writers to
publish articles about Lion Biotechnologies on investment websites as
well as to coordinate the distribution of articles to thousands of
electronic mailboxes; (3) former CEO Singh actively participated in the
promotional work for Lion Biotechnologies and understood that the
promotion firm was using writers who would not disclose that Lion
Biotechnologies was indirectly compensating them for their publications;
and (4) as a result, defendants’ public statements were materially false
and misleading at all relevant times. When the true details entered the
market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as
lead plaintiff, you must move the Court no later than June 13, 2017. If
you wish to join the litigation, go to http://www.rosenlegal.com/cases-1100.html
or to discuss your rights or interests regarding this class action,
please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at
866-767-3653 or via email at pkim@rosenlegal.com
or kchan@rosenlegal.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm
or on Twitter: https://twitter.com/rosen_firm.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Rosen Law Firm represents investors throughout the globe, concentrating
its practice in securities class actions and shareholder derivative
litigation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170420006109/en/
Contacts:
The Rosen Law Firm, P.A.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin
Chan, Esq.
275 Madison Avenue, 34th Floor
New York,
NY 10016
Tel: 212-686-1060
Toll Free: 866-767-3653
Fax:
212-202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
Source: The Rosen Law Firm, P.A.
© 2024 Canjex Publishing Ltd. All rights reserved.